Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

Anforth, Rachael; Liu, Mengmeng; Nguyen, Bao; Uribe, Pablo; Kefford, Richard; Clements, Arthur; Long, Georgina V.; Fernández‐Peñas, Pablo

doi:10.1111/ajd.12124

Cited by 67 publications

(60 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 In this study, we describe the cutaneous toxic effects arising in a large cohort of patients treated with a singleagent BRAF inhibitor (dabrafenib or vemurafenib) or a combination of dabrafenib and trametinib (CombiDT) for metastatic melanoma at a single institution.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

Agminated melanocytic nevus is an uncommon type of mole, characterized by a local group of macular or papular pigmented lesions, well demarcated, without a common pigmented background. This pattern has also been associated with Spitz nevi, dysplastic melanocytic nevi, and non-melanocytic lesions.We describe the onset of an acquired agminated melanocytic nevus after dabrafenib treatment. Our case highlights paradoxical MAPK activation in the setting of single-agent BRAF blockade and underscores the importance of characterizing the diverse side effects of selective BRAF inhibitors. This is the first case, to our knowledge, of agminated melanocytic nevus in association with dabrafenib.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The reported incidence of trametinib-induced acneiform reactions is 80%, 3,7 with much lower rates noted when trametinib is combined with dabrafenib. 5 Uribe et al 26 have…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most frequent cutaneous adverse events of dabrafenib are hyperkeratosis, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome. Trametinib is more frequently related with the development of acneiform dermatitis or alopecia 4,17 . Less is known about the cutaneous adverse events related to cobimetinib.…”

Section: Introductionmentioning

confidence: 99%

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma

Sanlorenzo

Choudhry

Vujic

et al. 2014

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background BRAF and MEK inhibitors frequently cause cutaneous adverse events. Objective To investigate the cutaneous safety profile of BRAF inhibitors versus BRAF- and MEK-inhibitor combination regimens. Methods We performed a retrospective cohort study, collecting data from 44 melanoma patients treated either with BRAF inhibitors (vemurafenib or dabrafenib) or BRAF- and MEK- inhibitor combination regimens (vemurafenib+cobimetinib or dabrafenib+trametinib). Patient characteristics, as well as the occurrence and severity of cutaneous adverse events are described. Results The development of cutaneous adverse events was significantly less frequent (p=0.012) and occurred after longer treatment time (p=0.025) in patients treated with BRAF- and MEK-inhibitor combination regimen compared to patients treated with BRAF inhibitor monotherapy. Among patients who received both BRAF inhibitor treatment and the combination of BRAF- and MEK-inhibitor at different time points during their treatment course, the development of squamous cell carcinoma or keratoacanthoma was significantly less frequent when they received the combination regimen (p=0.008). Patients receiving vemurafenib developed more cutaneous adverse events (p=0.001) and in particular more photosensitivity (p=0.010) than patients who did not. Limitations Limited number of patients. Conclusion Combination regimen with BRAF- and MEK-inhibitors shows fewer cutaneous adverse events and longer cutaneous adverse event-free interval compared to BRAF inhibitor monotherapy.

show abstract

“…In addition to xerosis, rashes, including papulopustular eruptions involving the face and chest, are also common dAEs of this drug, described in 75% to 85% of patients. 141,154,155 MEK is downstream of EGFR in the EGFR-Ras-Raf-MEK-ERK signaling pathway. 156,157 The effector role of MEK in this pathway likely explains the overlap of dAEs for trametinib and EGFR inhibitors.…”

Section: Discussionmentioning

confidence: 99%

Incidence and risk of xerosis with targeted anticancer therapies

Valentine

Belum

Duran

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

Abstract: The MEK inhibitor trametinib is associated with the development of acneiform eruptions. When combined with dabrafenib the frequency of this side-effect is reduced.

Cited by 67 publications

References 20 publications

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma

Incidence and risk of xerosis with targeted anticancer therapies

Contact Info

Product

Resources

About